Katlyn Nemani , Livia De Picker , Faith Dickerson , Marion Leboyer , Michele Santacatterina , Fumika Ando , Gillian Capichioni , Thomas E. Smith , Jamie Kammer , Kawtar El Abdellati , Manuel Morrens , Violette Coppens , Emily Katsafanas , Andrea Origoni , Sabahat Khan , Kelly Rowe , R.Sarah Ziemann , Ryad Tamouza , Robert H. Yolken , Donald C. Goff
{"title":"精神分裂症和分裂情感障碍患者对 SARS-CoV-2 mRNA 疫苗的抗穗状病毒抗体反应","authors":"Katlyn Nemani , Livia De Picker , Faith Dickerson , Marion Leboyer , Michele Santacatterina , Fumika Ando , Gillian Capichioni , Thomas E. Smith , Jamie Kammer , Kawtar El Abdellati , Manuel Morrens , Violette Coppens , Emily Katsafanas , Andrea Origoni , Sabahat Khan , Kelly Rowe , R.Sarah Ziemann , Ryad Tamouza , Robert H. Yolken , Donald C. Goff","doi":"10.1016/j.bbih.2024.100802","DOIUrl":null,"url":null,"abstract":"<div><h3>Importance</h3><p>Individuals with schizophrenia are at higher risk for severe COVID-19 illness and severe breakthrough infection following vaccination. It is unclear whether immune response to vaccination differs in this population.</p></div><div><h3>Objective</h3><p>To assess whether anti-SARS-CoV-2 spike antibody titers after vaccination differ in people with a diagnosis of schizophrenia or schizoaffective disorder (SZ) compared to controls without a psychiatric disorder.</p></div><div><h3>Design</h3><p>This cohort study assessed antibody response following the first and second dose of mRNA vaccines at longitudinal timepoints, up to 7 weeks following the first dose of vaccine.</p></div><div><h3>Setting</h3><p>A multi-center study including psychiatric healthcare settings in the United States and Europe.</p></div><div><h3>Participants</h3><p>205 adults with no history of COVID-19 infection, including 106 individuals with SZ and 99 controls without a psychiatric disorder, who received their first dose of SARS-CoV-2 mRNA vaccine between December 20, 2020 and May 27, 2021.</p></div><div><h3>Main outcomes and measures</h3><p>Mean SARS-CoV-2 anti-Spike IgG antibody levels within 7 weeks after the first dose of vaccination.</p></div><div><h3>Results</h3><p>A total of 205 individuals (mean [SD] age, 44.7 [12.0] years; 90 [43.9%] male) were included, of which 106 (51.7%) were diagnosed with SZ. SZ was associated with lower mean log antibody levels (−0.15; 95% CI, −0.27 to −0.03, <em>P</em> = 0.016) after adjusting for age, sex, body mass index, smoking, days since vaccination, and vaccine manufacturer. In secondary analyses of dose-specific responses, SZ was associated with a lower mean log antibody level after the second dose of vaccine (−0.23; 95% CI -0.39 to −0.06, <em>P</em> = 0.006), but not the first dose of vaccine (0.00; 95% CI -0.18— 0.19, <em>P</em> = 0.96).</p></div><div><h3>Conclusions and Relevance</h3><p>In this cohort study of individuals with SZ and a control group without psychiatric disorders, SZ was associated with lower SARS-CoV-2 anti-spike antibody levels following 2 doses of SARS-CoV-2 mRNA vaccination. This highlights the need for further studies assessing vaccine immunogenicity in individuals with schizophrenia.</p></div>","PeriodicalId":72454,"journal":{"name":"Brain, behavior, & immunity - health","volume":null,"pages":null},"PeriodicalIF":3.7000,"publicationDate":"2024-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666354624000802/pdfft?md5=be6f3f21a353c1ddec433f95d38a7fea&pid=1-s2.0-S2666354624000802-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Anti-spike antibody responses to SARS-CoV-2 mRNA vaccines in people with schizophrenia and schizoaffective disorder\",\"authors\":\"Katlyn Nemani , Livia De Picker , Faith Dickerson , Marion Leboyer , Michele Santacatterina , Fumika Ando , Gillian Capichioni , Thomas E. Smith , Jamie Kammer , Kawtar El Abdellati , Manuel Morrens , Violette Coppens , Emily Katsafanas , Andrea Origoni , Sabahat Khan , Kelly Rowe , R.Sarah Ziemann , Ryad Tamouza , Robert H. Yolken , Donald C. Goff\",\"doi\":\"10.1016/j.bbih.2024.100802\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Importance</h3><p>Individuals with schizophrenia are at higher risk for severe COVID-19 illness and severe breakthrough infection following vaccination. It is unclear whether immune response to vaccination differs in this population.</p></div><div><h3>Objective</h3><p>To assess whether anti-SARS-CoV-2 spike antibody titers after vaccination differ in people with a diagnosis of schizophrenia or schizoaffective disorder (SZ) compared to controls without a psychiatric disorder.</p></div><div><h3>Design</h3><p>This cohort study assessed antibody response following the first and second dose of mRNA vaccines at longitudinal timepoints, up to 7 weeks following the first dose of vaccine.</p></div><div><h3>Setting</h3><p>A multi-center study including psychiatric healthcare settings in the United States and Europe.</p></div><div><h3>Participants</h3><p>205 adults with no history of COVID-19 infection, including 106 individuals with SZ and 99 controls without a psychiatric disorder, who received their first dose of SARS-CoV-2 mRNA vaccine between December 20, 2020 and May 27, 2021.</p></div><div><h3>Main outcomes and measures</h3><p>Mean SARS-CoV-2 anti-Spike IgG antibody levels within 7 weeks after the first dose of vaccination.</p></div><div><h3>Results</h3><p>A total of 205 individuals (mean [SD] age, 44.7 [12.0] years; 90 [43.9%] male) were included, of which 106 (51.7%) were diagnosed with SZ. SZ was associated with lower mean log antibody levels (−0.15; 95% CI, −0.27 to −0.03, <em>P</em> = 0.016) after adjusting for age, sex, body mass index, smoking, days since vaccination, and vaccine manufacturer. In secondary analyses of dose-specific responses, SZ was associated with a lower mean log antibody level after the second dose of vaccine (−0.23; 95% CI -0.39 to −0.06, <em>P</em> = 0.006), but not the first dose of vaccine (0.00; 95% CI -0.18— 0.19, <em>P</em> = 0.96).</p></div><div><h3>Conclusions and Relevance</h3><p>In this cohort study of individuals with SZ and a control group without psychiatric disorders, SZ was associated with lower SARS-CoV-2 anti-spike antibody levels following 2 doses of SARS-CoV-2 mRNA vaccination. This highlights the need for further studies assessing vaccine immunogenicity in individuals with schizophrenia.</p></div>\",\"PeriodicalId\":72454,\"journal\":{\"name\":\"Brain, behavior, & immunity - health\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.7000,\"publicationDate\":\"2024-06-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2666354624000802/pdfft?md5=be6f3f21a353c1ddec433f95d38a7fea&pid=1-s2.0-S2666354624000802-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Brain, behavior, & immunity - health\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2666354624000802\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Brain, behavior, & immunity - health","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666354624000802","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
Anti-spike antibody responses to SARS-CoV-2 mRNA vaccines in people with schizophrenia and schizoaffective disorder
Importance
Individuals with schizophrenia are at higher risk for severe COVID-19 illness and severe breakthrough infection following vaccination. It is unclear whether immune response to vaccination differs in this population.
Objective
To assess whether anti-SARS-CoV-2 spike antibody titers after vaccination differ in people with a diagnosis of schizophrenia or schizoaffective disorder (SZ) compared to controls without a psychiatric disorder.
Design
This cohort study assessed antibody response following the first and second dose of mRNA vaccines at longitudinal timepoints, up to 7 weeks following the first dose of vaccine.
Setting
A multi-center study including psychiatric healthcare settings in the United States and Europe.
Participants
205 adults with no history of COVID-19 infection, including 106 individuals with SZ and 99 controls without a psychiatric disorder, who received their first dose of SARS-CoV-2 mRNA vaccine between December 20, 2020 and May 27, 2021.
Main outcomes and measures
Mean SARS-CoV-2 anti-Spike IgG antibody levels within 7 weeks after the first dose of vaccination.
Results
A total of 205 individuals (mean [SD] age, 44.7 [12.0] years; 90 [43.9%] male) were included, of which 106 (51.7%) were diagnosed with SZ. SZ was associated with lower mean log antibody levels (−0.15; 95% CI, −0.27 to −0.03, P = 0.016) after adjusting for age, sex, body mass index, smoking, days since vaccination, and vaccine manufacturer. In secondary analyses of dose-specific responses, SZ was associated with a lower mean log antibody level after the second dose of vaccine (−0.23; 95% CI -0.39 to −0.06, P = 0.006), but not the first dose of vaccine (0.00; 95% CI -0.18— 0.19, P = 0.96).
Conclusions and Relevance
In this cohort study of individuals with SZ and a control group without psychiatric disorders, SZ was associated with lower SARS-CoV-2 anti-spike antibody levels following 2 doses of SARS-CoV-2 mRNA vaccination. This highlights the need for further studies assessing vaccine immunogenicity in individuals with schizophrenia.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
